Tenpoint Therapeutics Ltd. is a global biotechnology company focused on the commercialization of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75% / 0.1%, the first and only dual agent eye drop for the treatment of presbyopia, a condition that affects nearly 128 million people in the U.S. and approximately 2 billion people globally. By understanding real-world needs and partnering with eye care professionals, Tenpoint is working to bring innovation to the aging eye.
Tenpoint therapeutics
Residents at Main Campus